Work

Changes in apolipoproteins following ingestion of a beverage delivering β-hydroxybutyrate: results from a randomized placebo-controlled trial

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background: -hydroxybutyrate (KEβHB) has been shown to reduce the circulating levels of remnant cholesterol and triglycerides. However, the mechanisms behind this action remain unknown. Aim: To investigate the effect of KEβHB supplementation on apolipoproteins and to study whether circulating levels of triglycerides play a role in this effect. Methods: The study was a randomized placebo-controlled trial, registered at https://www.clinicaltrials.gov/ (NCT03889210). It included 18 adults (12 men and 6 women) with prediabetes (defined as per the American Diabetes Association criteria). Following an overnight fast, participants ingested a KEβHB or a placebo beverage in a cross-over manner. Serial blood samples were collected from baseline to 150 min at intervals of 30 min. The endpoints were changes in apolipoprotein (apo) A-I, apo B, apo B-48, apo C-II, apo C-III, and apo E. Area under the curve (AUC) analyses were calculated to estimate changes in the studied apolipoproteins over time. Participants were further stratified into 'hypertriglyceridemia' and normal triglyceride levels subgroups. Results: = 0.023) in the overall cohort. No statistically significant differences in AUCs were found for the other studied apolipoproteins. The subgroup analysis showed significantly lower levels of apo B (and higher levels of apo C-II) after the KEβHB beverage in individuals with hypertriglyceridemia only. No significant associations were found for the other studied apolipoproteins in either subgroup. Conclusion: Exogenously induced acute ketosis resulted in a significantly elevated apo C-II compared with the placebo. Further, the levels of apo B were significantly lowered following ingestion of the KEβHB beverage only among individuals with hypertriglyceridemia. Acute nutritional ketosis may be considered as a potential approach to reduce atherogenic triglyceride-rich lipoproteins in individuals at high cardiovascular disease risk.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7128056980
FWCI:
Cites: 56
Cited by:
Related to: